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Papillomaviruses have been implicated in a variety of human diseases ranging from common warts to invasive carcinoma of
the anogenital mucosa. Existing assays for genotyping human papillomavirus are restricted to a small number of types. Here,
we present a comprehensive, accurate microarray strategy for detection and genotyping of 102 human papillomavirus types and
validate its use in a panel of 91 anal swabs. This array has equal performance to traditional dot blot analysis with the beneﬁts of
added genotype coverage and the ability to calibrate readout over a range of sensitivity or speciﬁcity values.
1.Introduction
Papillomaviruses are a group of nonenveloped, epithelio-
tropic DNA viruses that infect the skin and mucous mem-
branes of humans and animals. There are over 100 diﬀerent
human papillomaviruses (HPV), which are associated with
disease of the skin, mucous membranes, and aerodigestive
tract. HPV infection leads to lesions ranging from common
and genital warts to laryngeal papillomatosis, to epithelial
cancers, particularly cervical carcinoma and a subset of head
and neck squamous cell carcinoma (HNSCC). Detection of
papillomavirus is usually based on molecular assays for viral
nucleic acid [1].
Thereisconsiderablesequencediversitywithinthefamily
papillomaviridae. The HPVs fall into ﬁve genera: alphapapil-
lomavirus(α-PV), betapapillomavirus(β-PV), gammapapil-
lomavirus (γ-PV), mupapillomavirus (μ-PV), and nupapil-
lomavirus (ν-PV). The mucosal α-PV are the best described,
due to their association with genital malignancy. There are
thirteen types of high-risk mucosal α-PV associated with
cervical and anal intraepithelial neoplasia: 16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, and 68. It has recently been
recommended that HPV 66 be added to this high-risk group
[2]. HPV testing is becoming increasingly important as a
screening tool, in combination with cytology, for HPV-
associated neoplasia [3, 4].
Most commercial assays for alphapapillomaviruses are
limited to the high-risk types, which are relevant for use in
the clinical setting but provide limited information in the
research setting. The current FDA-approved tests for HPV
are the DigeneHybrid Capture 2 (HC2)test and the Cervista
HPV16/18 and HR test. HC2 combines antibody capture
and chemiluminescent signal detection to detect 13 high-
risk HPV types (Digene Corporation, Gaithersburg, Md,
USA), while the Cervista HR uses invader chemistry to
detect 14 high risk types (Hologic, Inc., Bedford, Mass,
USA) [5]. While both of these assays have good sensitivity
and speciﬁcity for cervical neoplasia, neither speciﬁcally
genotypes the HPV infection.
There are currently no genotyping assays that cover mul-
tiple HPV genera. The majority of laboratory tests use
PCR ampliﬁcation with degenerate or multiplex primer sets2 Journal of Nucleic Acids
followed by genotype readout with sequencing or blot, or
bead-based Multiplexing [6–13]. A number of groups have
developed microarray strategies for detection of HPV, but
these have been limited to targeted PCR and array readout
of a speciﬁc subset of HPV types [14–23].
The obstacle to a comprehensive detection strategy is
the sequence diversity of HPVs. Standard PCR assays are
sensitive, butit is diﬃcult to designprimers to detect a broad
range ofpapillomavirus types. Here,we present a microarray
strategy for the detection and genotyping of 102 HPV types
representing all genera and validate its use in a large panel of
anal swabs from an HPV cohort study.
2.Materialsand Methods
2.1. Sample Material. Ninety-one samples were assayed,
drawn from a previously reported cohort study of HPV
infection in the anal canal of homosexual and bisexual
men [24]. The study was approved by the University of
California, San Francisco Committee on Human Research,
and informed consent was obtained from all subjects. As
reported in that study, all samples were typed for HPV with
MY09/MY11 consensus HPV-L1 primers [9] followed by dot
blot with type-speciﬁc biotinylated probes for HPV types 6,
11, 16, 18, 26, 31, 32, 33, 35, 39, 40, 45, 51, 52, 53, 54, 55,
56, 58, 59, 61, 66, 68, 69, 70, 73, 82 variant, 83, and 84,
as well as the following 10 HPV types together in a probe
mixture: 2, 13, 34, 42, 57, 62, 64, 67, 72, and 82 [24]. These
samples were drawn from a populationwith more multiplic-
ity of types than a typical cervical sample set from healthy
women.
2.2. Array Design. 60nt oligonucleotide probes were de-
signedbasedonthefullsequencesofthe102full-lengthHPV
genomes listed in GenBank on January 6, 2009 (see Supple-
mentary File 1 in Supplementary Material available online
at doi: 10.406/2011/756905). Genotype-speciﬁc probes were
designed using ArrayOligoSelector [25], a design pack-
age that addresses several design considerations including
uniqueness, sequence complexity, self-annealing as a mea-
sure of secondary structure, and GC content (http://deri-
silab.ucsf.edu/index.php?page=software).Ten probes were
selected for each genome with a target GC content of 30%
and a maximum binding energy cutoﬀ of −45kcal/mol.
Sequences containing AT regions longer than 20bp and less
than 10% of non-AT nucleotides were excluded from probe
selection. A second set of genotype-speciﬁc probes were
generatedusing a tiling strategy, with an oﬀs e to f2 0n ta c r o s s
thewholegenomeandanoﬀsetof5ntovertheL1region,the
region traditionally used for genotyping. These probes were
ﬁltered for a predicted binding energy of <−45kcal/molwith
their source HPV species and a predicted binding energy
of >−10kcal/mol against all other HPV species. All probes
were ﬁltered against nonspeciﬁc binding to the human
genome.
Additional probes were designed to cover conserved re-
gions in each genus using a variation on a previously de-
scribed strategy [26]. Each fully sequenced genome was
divided into overlapping 60nt segments oﬀset by 30nt, and
a pairwise nucleotide BLAST [27] was performed between
each potential probe and each viral genome. The top-
ranked probe was selected, and the process was repeated
iteratively on each sequence lacking signiﬁcant homology to
the selected probe until each genome was covered by at least
ﬁve conserved probes with a predicted binding energy of
<−45kcal/mol. All probes were ﬁltered against nonspeciﬁc
binding to the human genome.
Overall, 14,161 60-mer oligonucleotide probes and their
corresponding reverse complements were designed. The
array was synthesized on the Agilent 8x60K SurePrint G3
custom array platform (Agilent Technologies, Santa Clara,
Calif, USA). Each of the 28,322 probes was printed in du-
plicate (Supplementary File 2).
2.3. Array Hybridization. DNA was randomly ampliﬁed
and labeled with Cy3 using an adaptation of a previously
described protocol without the reverse transcription step
[28]. In parallel, HeLa cell DNA was used as a positive
ampliﬁcation and hybridization control, and water was used
as a negative control. Array hybridization was performed
with the AgilentGene Expression Hybridization Kit, adapted
from manufacturer’s speciﬁcations with the following mod-
iﬁcation: nuclease-free water substituted for fragmentation
buﬀer. Arrays were washed using Agilent Wash Buﬀer Kit,
according to manufacturer’s speciﬁcations, and scanned
using Agilent Scan Control A.8.1.3 software. Data were
extractedfromthescannedarrayimageusingAgilentFeature
Extraction version 10.5.1.1 Software.
2.4. Array Analysis. Values from replicate spots on the array
were averaged for analysis, and data were analyzed using
the E-Predict algorithm [29]. An E-matrix was generated
from theoretical energy proﬁles for each of the 102 full-
length HPV genomes in the design set, matched against
each of the array probes. E-Predict compares this theoretical
E-matrix proﬁle to the observed hybridization pattern on
an array to generate a similarity score and rank order of
likelihood for each genome. E-Predict was run with unit
vectorplusquadraticmatrix normalization, unitvectorarray
normalization, and a dot product distance metric.
A set of uninformative oligonucleotides were deﬁned as
probes with signiﬁcant autoﬂuorescence when hybridized to
water and probeswith cross-hybridization tohuman DNAin
atestingsetofHPV-negativespecimens.Thesewereexcluded
from E-Predict analysis.
2.5. Sequence Genotyping of HPV. α-HPV PCR was per-
formed using thenested primersetsMY09-MY011 and GP5-
GP6, as previously described in [9, 13]. The PCR products
were visualized by agarose gel electrophoresis, and ampli-
cons of correct size were gel puriﬁed using the PureLink
Quick Gel Extraction Kit (Invitrogen, Carlsbad, Calif, USA).
Gel-puriﬁed DNA was inserted into pCR2.1 TOPO vec-
tor (Invitrogen) and transformed into chemically competent
TOP10 E. coli (Invitrogen), according to manufacturer’s
speciﬁcations. For each DNA sample, 12 transformantJournal of Nucleic Acids 3
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Figure1:ArrayperformanceforHPV18.(a)Cleardemarcationamongsimilarityscoresbetween positiveandnegative samples.(b)Receiver-
operating characteristic curve for HPV18.
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Figure 2: Receiver operating characteristic curve of the microarray
for 91 anal swab samples tested for 102 HPV genotypes.
colonies were selected for PCR insert ampliﬁcation using
M13 forward-reverse primers followed by sequencing on the
ABI 3130xl Genetic Analyzer (Applied Biosystems, Carlsbad,
Calif, USA).
2.6. Statistical Analysis. A receiver-operating characteristic
(ROC) curve was generated to assess the similarity score
for each of the 102 possible HPV genotype outcomes on
array with the actual genotype(s) detected by sequencing
of the 91 samples, for a total of 9282 tests. Sensitivity and
speciﬁcity for the array were calculated with similarity score
cutoﬀ values of 0.035 and 0.1. Sensitivity and speciﬁcity
were calculated for the blot based on the 29 types covered,
for a total of 2639 tests. Agreement and Cohen’s kappa
coeﬃcients were calculated for the blot versus the array for
the 29 types covered on the blot. All statistical analysis was
performed with Stata 11 (StataCorp LP, College Station, Tex,
USA).
3.Results
28,322 60-mer oligonucleotide probes were designed and
printed on the array. An E-matrix was generated to reﬂect
the theoretical hybridization energies of each genome in
the design set to each oligonucleotide on the array. This
matrix was used for E-Predict analysis of biological samples
hybridized to the array.
Performance of the array for one representative HPV
type, HPV18, is demonstrated in Figure 1. The HeLa cervical
cancer cell line, which contains integrated HPV18, was
used as a positive control, and water was used as a negative
control. The range of similarity scores for HPV18 showed
a clear demarcation between positive and negative controls
(Figure 1(a)), and a ROC curve was generated with an
area under the curve of 0.9795 (Figure 1(b)), a near-perfect
classiﬁcation.
To characterize the performance of the array across all
genomes, DNA from 91 anal swab samples was randomly
ampliﬁed and hybridized to the array. For each specimen
run on the array, a similarity score was generated for each
of the 102 HPV genotypes in the E-matrix, generating 9,282
observations.These resultswerecomparedtoagoldstandard
of PCR and sequencing. A ROC curve was generated with an
area under the curve of 0.8287 (Figure 2).
Based on the ROC curve, two similarity score cut-points
were generated for sensitivity and speciﬁcity calculations
(Table 1). A score of 0.035 yielded a sensitivity of 0.72 and
a speciﬁcity of 0.76 for the 102 genotypes in the E-matrix. A
score of 0.1 yielded a sensitivity of 0.41 and a speciﬁcity of
0.99 for the same 102 types.
Each of the samples had previously been genotyped for
HPV with a PCR and blot assay that covers 29 individual
types and a probe mixture that detects ten additional types
but does not discriminate between them. Compared to PCR
and sequencing, the blot had a sensitivity of 0.41 and a
speciﬁcity of 0.98 for the 29 speciﬁc types covered, similar
to the array cut-point of 0.1. For the 29 types covered on4 Journal of Nucleic Acids
Table 1: Comparison of array performance to blot. P values: Fisher’s exact test.
Test Blot Array (s ≥ 0.1) Array (s ≥ 0.035)
Sequence Positive Negative Positive Negative Positive Negative
Test result + 55 52 63 115 112 2163
Test result − 80 2452 94 9010 45 6962
Sensitivity .407 .401 .713
Speciﬁcity .979 .987 .763
P value <.0001 <.0001 <.0001
Table 2: Array detection of 11 HPV types not covered by the blot.
HPV type Array positive Array negative
12 0 1
34 1 0
44 1 0
cand62 2 1
67 1 0
71 2 0
72 3 0
81 5 1
cand85 1 1
97 1 0
102 1 0
Total 18 4
the blot, the two assays had an agreement of 96.6%, kappa
0.6, representing good agreement [30].
Among the 91 samples, 157 instances of 34 HPV types
were detected by PCR and sequencing. The types detected
were HPV 6, 11, 12, 16, 18, 26, 31, 33, 34, 35, 40, 44, 45,
52, 53, 54, 55, 56, 58, 59, 61, cand62, 66, 67, 70, 71, 72, 81,
82, 83, 84, cand85, 97, and 102. Among those, there were 22
instances of 11 types which were not speciﬁcally covered by
the blot strategy. Eighteen of these 22 infections (82%) were
detected on the microarray (Table 2).
4.Discussion
We demonstrate the performance of a comprehensive mi-
croarray for detection and genotyping of HPV and validate
this system on a large panel of anal swab samples. Previous
microarrays for HPV genotyping were designed to read out
multiplex or degenerate PCR ampliﬁcation and targeted
a small number of HPV types. The main beneﬁt of this
system is its accuracy for broad range of HPV genotypes, as
demonstrated by an area under the ROC curve of 0.8287.
Because the nucleic acid ampliﬁcation is not reliant on
degenerate or multiplex PCR, any HPV type present in the
sample may be detected.
In this sample set, an s value cutoﬀ of 0.1 yielded a
sensitivity of 0.41 and speciﬁcity of 0.99. This cutoﬀ favors
speciﬁcity over sensitivity, a feature common to many
HPV assays in clinical use. This is based on the prevalent
assumption that extremely low levels of HPV in a sample are
likely not clinically relevant. One example of this in practice
is the blot assay used to characterize this sample set in a
previously reported study [24]. Our array performance was
similar to that of the blot assay (sensitivity 0.41, speciﬁcity
0.98) with the beneﬁt of 61 additional HPV types covered on
thearray.Inthiscohortof91samples,therewere22instances
of 11 HPV types not present on the blot, of which 82% were
detected by the microarray. This demonstrates the beneﬁt of
additional type coverage in a genotyping strategy.
As well as covering more HPV types, our assay is more
ﬂexible than the standard array readout system. Because the
similarity score is a continuous variable, the cutoﬀ can be
tailored to the needs of the assay system. The similarity score
cutoﬀ that optimized both sensitivity and speciﬁcity was at
a score of 0.035 (Figure 2). This yielded a sensitivity of 0.71
and speciﬁcity of 0.76 compared with PCR and sequencing.
We validated the performance of this microarray by a
comparison to a gold standard of sequence genotyping.
No previous study has reported microarray sensitivity and
speciﬁcity withthistypeofvalidation.Some studiesreported
limits of detection and the absence of cross-hybridization
but did not address true sensitivity and speciﬁcity [16, 20,
21]. Other studies compared array performance to other
targeted HPV assays rather than to a gold standard of
sequencing. Thus, the authors were only able to report
interassay agreement or Cohen’s kappa. Ermel et al. com-
pared performance of α-PV detection with the Digene
Hybrid Capture II Assay, the Roche Linear Array Assay,
and the Kurabo GeneSquare Assay and reported a sample
proportion of agreement ranging from 0.86 to 0.89 between
the three assays. In two studies assessing multiplex PCR and
array primer extension (APEX), Gheit et al. compared their
arrays to reverse line blot or to one-step PCR and reverse
hybridization with overall kappas of 0.55 and 0.5. In those
studies, only a few samples were selected for sequencing to
conﬁrm array detection of types not seen on the other assays
[14, 15]. In our study, we measured a sample proportion
of agreement of 0.97 between the array and blot, with a
kappa of 0.6. This level of agreement demonstrates the
excellent performance of our system compared to previ-
ously reported arrays.The drawback to comparing assays
with diﬀerent types of coverage is that the agreement can
only be assessed for the overlapping types, which under-
estimates the utility of a comprehensive array such as this
one.
A number of arrays targeting the high-risk α-PV have
been evaluated by calculating the sensitivity and speciﬁcity
of the test for a cytologic diagnosis of neoplasia, which mayJournal of Nucleic Acids 5
be clinically relevant for a screening diagnostic but does not
address the performance of the assay in genotyping HPV
[18, 19, 22,23,31].Futurestudiesmay address thesensitivity
and speciﬁcity of our assay for cervical or anal intraepithelial
neoplasia.
The theoreticalE-matrix ofenergyproﬁlesusedtogener-
ate similarity scores was created from the 102 HPV genomes
used for oligonucleotide probe design. However, the E-
matrix canbeexpandedtoincludeadditionalpapillomavirus
genomes if desired, allowing for an updated genotyping
strategy without the synthesis of additional probes. This
ﬂexibility will lend itself to future studies as the number of
complete papillomavirus sequences continues to expand. As
vaccinationforHPVtypes6,11,16,and18increases, wemay
see a shift in HPV prevalence and the rise of less common
types. This assay is well suited to detect these trends.
Overall, this microarray provides a comprehensive and
accuratesolutionforthedetectionandgenotypingofabroad
spectrum ofHPVtypes. It will lenditself to high-throughput
applications such as screening of tumor cohorts and large
epidemiologic studies.
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